Sibel Blau, MD, elaborates on how cancer practices have adapted during the pandemic

New draft guidance from the FDA seeks to better define when a confirmatory trial is considered “underway” and more as part of the accelerated approval process. Doctors weigh in.

8 physician jobs in high demand. How does your job rank?

A study found worse esophagectomy outcomes at private equity–acquired centers; however, one expert warns against broad conclusions about private equity involvement.

Three oncology stories placed in the top five at this year’s Shkreli Awards, which highlight “the worst examples of profiteering and dysfunction in healthcare.”

Despite the collapse of legislation to reform PBMs and enact other policy fixes, community oncology advocates see opportunities with a new Congress.

Although most cancer care is now delivered in a team-based model, a group of practice advocates recently highlighted the lack of incentives for the entire care team.

What to make of Trump’s selections for the NIH, FDA, CDC, CMS, and more.

From 2020 to 2022, industry payments to peer reviewers hit $1.06 billion, with oncology among the top fields involved. Experts are calling for more transparency.

After a well-publicized split with Dana-Farber Cancer Institute, Mass General Brigham has launched its own cancer institute with big ambitions.

The FDA’s Accelerated Approval Program allows for quicker access to new drugs. However, data show patients wouldn’t trade speedy access for certainty of benefit.

Authors of a recent commentary argue that failure in confirmatory trials for drugs granted FDA accelerated approval does not necessarily constitute failed drugs.

The surgeon and TV personality has supported universal healthcare and has clashed with healthcare leaders on several fronts.